Fig. 1From: Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomesThe mutation site on NFE2L2 affecting the downstream expression of key genes, including NQO1, HMOX1, GCLM, and GCLCBack to article page